Sadeer G Al-Kindi1, Ghaith F Abu-Zeinah2, Chang H Kim1, Vittal Hejjaji3, Basem M William4, Paolo F Caimi4, Guilherme H Oliveira5. 1. Onco-cardiology program, Harrington Heart and Vascular Institute, and Seidman Cancer Center, University Hospitals, Cleveland, OH; School of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH. 2. New York Presbyterian Hospital, Weill Cornell Medical College, New York, NY. 3. Onco-cardiology program, Harrington Heart and Vascular Institute, and Seidman Cancer Center, University Hospitals, Cleveland, OH. 4. School of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH; University Hospitals Seidman Cancer Center, Cleveland, OH. 5. Onco-cardiology program, Harrington Heart and Vascular Institute, and Seidman Cancer Center, University Hospitals, Cleveland, OH; School of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH; University Hospitals Seidman Cancer Center, Cleveland, OH. Electronic address: guilherme.oliveira@uhhospitals.org.
Abstract
BACKGROUND: Over the past decades, survival of patients with Hodgkin lymphoma (HL) has increased but remains curtailed by cardiovascular mortality (CVM). HL survivors at greatest risk for cardiovascular death have not been clearly identified. We sought to report trends of CVM identify HL survivors at highest risk. METHODS: The Surveillance, Epidemiology, and End Results (SEER) database was queried for all adult patients diagnosed with HL (age 20-49 years) between 1990 and 2011. The trend of CVM and disparities are presented. RESULTS: Of 19,781 HL patients, 53% were male and 83% were white; patients had a mean age of 33 ± 8.3 years at diagnosis. Eighteen percent had stage I disease, 45% stage II, 18% stage III, and 15% stage IV. The risk for CVM was higher in blacks (adjusted hazard ratio [HR], 1.97; P = .002), men (adjusted HR, 2.2; P < .001), and patients with older age at diagnosis (adjusted HR, 1.073 per year; P < .001). CVM has decreased, with 5-year cumulative incidence decreasing from 1.17% in 1990 to 0.18% in 2006, averaging 7% per year (adjusted HR, 0.927; P < .001). This trend was seen only in patients with early disease (P < .001) but not with advanced disease (P = NS). CVM as a proportion of all-cause mortality increases sharply at 50 years of age, constituting more than 30% of all causes of death. CONCLUSION: Despite an overall decrease in CVM in HL survivors over the last decades, older patients, black patients, and men, especially those who have advanced-stage disease at diagnosis, are at the highest risk of cardiovascular death. Cardiovascular screening and risk modification should be intensified in HL patients with these characteristics.
BACKGROUND: Over the past decades, survival of patients with Hodgkin lymphoma (HL) has increased but remains curtailed by cardiovascular mortality (CVM). HL survivors at greatest risk for cardiovascular death have not been clearly identified. We sought to report trends of CVM identify HL survivors at highest risk. METHODS: The Surveillance, Epidemiology, and End Results (SEER) database was queried for all adult patients diagnosed with HL (age 20-49 years) between 1990 and 2011. The trend of CVM and disparities are presented. RESULTS: Of 19,781 HL patients, 53% were male and 83% were white; patients had a mean age of 33 ± 8.3 years at diagnosis. Eighteen percent had stage I disease, 45% stage II, 18% stage III, and 15% stage IV. The risk for CVM was higher in blacks (adjusted hazard ratio [HR], 1.97; P = .002), men (adjusted HR, 2.2; P < .001), and patients with older age at diagnosis (adjusted HR, 1.073 per year; P < .001). CVM has decreased, with 5-year cumulative incidence decreasing from 1.17% in 1990 to 0.18% in 2006, averaging 7% per year (adjusted HR, 0.927; P < .001). This trend was seen only in patients with early disease (P < .001) but not with advanced disease (P = NS). CVM as a proportion of all-cause mortality increases sharply at 50 years of age, constituting more than 30% of all causes of death. CONCLUSION: Despite an overall decrease in CVM in HL survivors over the last decades, older patients, black patients, and men, especially those who have advanced-stage disease at diagnosis, are at the highest risk of cardiovascular death. Cardiovascular screening and risk modification should be intensified in HL patients with these characteristics.
Authors: Graça M Dores; Rochelle E Curtis; Nicole H Dalal; Martha S Linet; Lindsay M Morton Journal: J Clin Oncol Date: 2020-09-18 Impact factor: 44.544
Authors: Lili Zhang; Shady Abohashem; Michael T Osborne; Nicki Naddaf; Rebecca Park; Kelvin Moore; Tomas Patrich; Steven G Deeks; Priscilla Y Hsue; Ahmed A Tawakol Journal: J Acquir Immune Defic Syndr Date: 2021-05-01 Impact factor: 3.771
Authors: Helen Strongman; Sarah Gadd; Anthony A Matthews; Kathryn E Mansfield; Susannah Stanway; Alexander R Lyon; Isabel Dos-Santos-Silva; Liam Smeeth; Krishnan Bhaskaran Journal: JACC CardioOncol Date: 2022-03-15
Authors: Melanie R Keats; Scott A Grandy; Nicholas Giacomantonio; David MacDonald; Miroslaw Rajda; Tallal Younis Journal: Pilot Feasibility Stud Date: 2016-08-05